2026-06-29T07:44:56Zhttps://docta.ucm.es/rest/oai/requestoai:docta.ucm.es:20.500.14352/987592025-07-08T23:49:30Zcom_20.500.14352_14col_20.500.14352_15
Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis
López Sánchez, Alicia
Pérez Cantero, Alba
Torrado Salmerón, Carlos Félix
Martín Vicente, Adela
García Herrero, Víctor
González Nicolás González, María Ángeles
Lázaro Fernández, Alberto
Tejedor Jorge, Alberto
Torrado Durán, Santiago
García Rodríguez, Juan José
Capilla, Javier
Torrado Durán, Susana
663/665
615.28
576.8
Aspergillosis
Aphotericin B
Deoxycholate
Pulmonary concentrations
Nephrotoxicity
Efficacy
Microbiología (Farmacia)
Parasitología (Farmacia)
Tecnología de los alimentos
32 Ciencias Médicas
23 Química
An experimental micellar formulation of 1:1.5 amphotericin B-sodium deoxycholate (AMB:DCH 1:1.5) was obtained and characterized to determine its aggregation state and particle size. The biodistribution, nephrotoxicity, and efficacy against pulmonary aspergillosis in a murine model were studied and compared to the liposomal commercial formulation of amphotericin B after intravenous administration. The administration of 5 mg/kg AMB:DCH 1:1.5 presented 2.8-fold-higher lung concentrations (18.125 ± 3.985 μg/g after 6 daily doses) and lower kidney exposure (0.391 ± 0.167 μg/g) than liposomal commercial amphotericin B (6.567 ± 1.536 and 5.374 ± 1.157 μg/g in lungs and kidneys, respectively). The different biodistribution of AMB:DCH micelle systems compared to liposomal commercial amphotericin B was attributed to their different morphologies and particle sizes. The efficacy study has shown that both drugs administered at 5 mg/kg produced similar survival percentages and reductions of fungal burden. A slightly lower nephrotoxicity, associated with amphotericin B, was observed with AMB:DCH 1:1.5 than the one induced by the liposomal commercial formulation. However, AMB:DCH 1:1.5 reached higher AMB concentrations in lungs, which could represent a therapeutic advantage over liposomal commercial amphotericin B-based treatment of pulmonary aspergillosis. These results are encouraging to explore the usefulness of AMB:DCH 1:1.5 against this disease.
Universidad Complutense de Madrid
Ministerio de Economía, Comercio y Empresa (España)
European Commission
Comunidad de Madrid
Instituto de Salud Carlos III
Depto. de Farmacia Galénica y Tecnología Alimentaria
Depto. de Fisiología
Depto. de Medicina
Depto. de Microbiología y Parasitología
Fac. de Farmacia
Instituto Universitario de Farmacia Industrial
Fac. de Medicina
TRUE
pub
2024-02-05T10:07:59Z
2024-02-05T10:07:59Z
2018
journal article
VoR
https://hdl.handle.net/20.500.14352/98759
0066-4804
10.1128/aac.00489-18
1098-6596
eng
info:eu-repo/grantAgreement/PI14/2F01195/ES
info:eu-repo/grantAgreement/ISCIII-RETIC/REDinREN/RD16/ 0009/0026
info:eu-repo/grantAgreement/B2017/BMD-3686
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F00276/ES/INTERVENCIONES TERAPEUTICAS SOBRE LAS BALSAS DE COLESTEROL EPITELIALES DESTINADAS A EVITAR LA FASE DE AMPLIFICACION DEL DAÑO ORGANICO AGUDO/
López Sánchez, A., Pérez Cantero, A., Torrado Salmerón, C. F. et al. «Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis». Antimicrobial Agents and Chemotherapy, vol. 62, n.o 7, julio de 2018, pp. e00489-18. https://doi.org/10.1128/AAC.00489-18.
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
restricted access
application/pdf
American Society for Microbiology